Across TCGA pan-cancer cohorts, CYB5D1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYB5D1 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CYB5D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYB5D1 expression acts as an unfavorable survival marker.
UCEC and LUAD are the cancer types where CYB5D1 Mutation most reproducibly stratifies survival.